Clinical and economic consequences of switching from omalizumab to mepolizumab in uncontrolled severe eosinophilic asthma

Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma

Héctor Ortega, Mark C. Liu, Ian Pavord et al. · New England Journal of Medicine · 2014 · 2.2K citations · Full text

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial

Ian Pavord, Stephanie Korn, Peter Howarth et al. · The Lancet · 2012 · 2.2K citations

Asthma, Severe Eosinophilic Asthma, Allergy +10

Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE

Marc Humbert, Richard Beasley, Jon G. Ayres et al. · Allergy · 2004 · 1.1K citations · Full text

Effect of asthma exacerbations on health care costs among asthmatic patients with moderate and severe persistent asthma

Jasmina Ivanova, Rachel Bergman, Howard G. Birnbaum et al. · Journal of Allergy and Clinical Immunology · 2012 · 299 citations

Asthma, Severe Persistent Asthma, Pulmonary Care +9

A comprehensive study of the direct and indirect costs of adult asthma

Miriam G. Cisternas, Paul D. Blanc, Irene H. Yen et al. · Journal of Allergy and Clinical Immunology · 2003 · 279 citations · Full text

Asthma, Comprehensive Study, Indirect Costs +9